T2 Biosystems, Inc. (LON: 0A57)
London
· Delayed Price · Currency is GBP · Price in USD
0.219
-0.009 (-4.12%)
At close: Jan 30, 2025
T2 Biosystems Revenue
T2 Biosystems had revenue of $1.99M USD in the quarter ending September 30, 2024, with 34.85% growth. This brings the company's revenue in the last twelve months to $7.68M, down -30.19% year-over-year. In the year 2023, T2 Biosystems had annual revenue of $7.19M, down -67.75%.
Revenue (ttm)
$7.68M
Revenue Growth
-30.19%
P/S Ratio
n/a
Revenue / Employee
$67.94K
Employees
113
Market Cap
3.64M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.19M | -15.11M | -67.75% |
Dec 31, 2022 | 22.31M | -5.75M | -20.50% |
Dec 31, 2021 | 28.06M | 9.93M | 54.76% |
Dec 31, 2020 | 18.13M | 9.80M | 117.52% |
Dec 31, 2019 | 8.34M | -2.16M | -20.62% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
Shell | 227.10B |
HSBC Holdings | 43.25B |
Unilever | 51.12B |
Rio Tinto Group | 42.87B |
RELX PLC | 9.30B |
British American Tobacco p.l.c. | 26.18B |
BP p.l.c. | 144.69B |
T2 Biosystems News
- 26 days ago - T2 Biosystems reports preliminary Q4 product revenues of $2.3M - Seeking Alpha
- 6 weeks ago - T2 Biosystems sells four T2Dx Instruments to European distributor - Seeking Alpha
- 6 weeks ago - T2 Biosystems announces extension of multi-year capital equipment supplier agreement with Vizient - Seeking Alpha
- 6 weeks ago - T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc. - GlobeNewsWire
- 7 weeks ago - T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens - GlobeNewsWire
- 2 months ago - T2 Biosystems, Inc. (TTOO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024 - GlobeNewsWire
- 4 months ago - T2 Biosystems, Inc. (TTOO) Business Update Conference Call Transcript - Seeking Alpha